Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One to Three trial
PACTR202304463210784Phase 4Not yet recruiting
- Sponsor
- Aurum Institute
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rifapentine and isoniazid in Tuberculosis (TB) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by Aurum Institute. Primary endpoints: Treatment completion with high adherence and Safety of treatment regimens. Planned start May 2023; status: not yet recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202304463210784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202304463210784.